NYSE:USNA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$2.0b

Last Updated

2021/06/23 06:10 UTC

Data Sources

Company Financials +

Executive Summary

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. More Details


Snowflake Analysis

Flawless balance sheet with outstanding track record.


Similar Companies

Share Price & News

How has USANA Health Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: USNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: USNA's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-2.1%

USNA

-1.3%

US Personal Products

-0.1%

US Market


1 Year Return

40.5%

USNA

55.1%

US Personal Products

39.0%

US Market

Return vs Industry: USNA underperformed the US Personal Products industry which returned 56.3% over the past year.

Return vs Market: USNA underperformed the US Market which returned 39% over the past year.


Shareholder returns

USNAIndustryMarket
7 Day-2.1%-1.3%-0.1%
30 Day-3.5%0.6%2.6%
90 Day6.0%4.6%8.0%
1 Year40.5%40.5%56.4%55.1%41.2%39.0%
3 Year-12.1%-12.1%73.1%66.7%62.4%52.3%
5 Year86.1%86.1%126.4%109.0%132.3%106.2%

Long-Term Price Volatility Vs. Market

How volatile is USANA Health Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is USANA Health Sciences undervalued compared to its fair value and its price relative to the market?

24.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: USNA ($101.16) is trading below our estimate of fair value ($133.85)

Significantly Below Fair Value: USNA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: USNA is good value based on its PE Ratio (16.5x) compared to the US Personal Products industry average (16.7x).

PE vs Market: USNA is good value based on its PE Ratio (16.5x) compared to the US market (19.2x).


Price to Earnings Growth Ratio

PEG Ratio: USNA is poor value based on its PEG Ratio (12.3x)


Price to Book Ratio

PB vs Industry: USNA is overvalued based on its PB Ratio (5.1x) compared to the US Personal Products industry average (3.1x).


Future Growth

How is USANA Health Sciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

1.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: USNA's forecast earnings growth (1.3% per year) is below the savings rate (2%).

Earnings vs Market: USNA's earnings (1.3% per year) are forecast to grow slower than the US market (15.7% per year).

High Growth Earnings: USNA's earnings are forecast to grow, but not significantly.

Revenue vs Market: USNA's revenue (5.2% per year) is forecast to grow slower than the US market (9.4% per year).

High Growth Revenue: USNA's revenue (5.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if USNA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has USANA Health Sciences performed over the past 5 years?

5.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: USNA has high quality earnings.

Growing Profit Margin: USNA's current net profit margins (10.9%) are higher than last year (9.8%).


Past Earnings Growth Analysis

Earnings Trend: USNA's earnings have grown by 5.7% per year over the past 5 years.

Accelerating Growth: USNA's earnings growth over the past year (24.6%) exceeds its 5-year average (5.7% per year).

Earnings vs Industry: USNA earnings growth over the past year (24.6%) exceeded the Personal Products industry 7.6%.


Return on Equity

High ROE: USNA's Return on Equity (32%) is considered high.


Financial Health

How is USANA Health Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: USNA's short term assets ($373.2M) exceed its short term liabilities ($151.5M).

Long Term Liabilities: USNA's short term assets ($373.2M) exceed its long term liabilities ($30.3M).


Debt to Equity History and Analysis

Debt Level: USNA is debt free.

Reducing Debt: USNA has no debt compared to 5 years ago when its debt to equity ratio was 26.3%.

Debt Coverage: USNA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: USNA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is USANA Health Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate USNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate USNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if USNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if USNA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of USNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Kevin Guest (57 yo)

4.58yrs

Tenure

US$3,960,410

Compensation

Mr. Kevin G. Guest serves as Chairman of the Board of USANA Health Sciences, Inc. since May 1, 2020 and its Chief Executive Officer since November 23, 2016. Mr. Guest served as Co-Chief Executive Officer o...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD3.96M) is about average for companies of similar size in the US market ($USD3.71M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: USNA's management team is considered experienced (4.6 years average tenure).


Board Members

Experienced Board: USNA's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: USNA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

USANA Health Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: USANA Health Sciences, Inc.
  • Ticker: USNA
  • Exchange: NYSE
  • Founded: 1992
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: US$2.047b
  • Shares outstanding: 20.24m
  • Website: https://www.usana.com

Number of Employees


Location

  • USANA Health Sciences, Inc.
  • 3838 West Parkway Boulevard
  • Salt Lake City
  • Utah
  • 84120
  • United States

Listings


Biography

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/23 06:10
End of Day Share Price2021/06/22 00:00
Earnings2021/04/03
Annual Earnings2021/01/02


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.